Aragen slashes drug development time with CHOMax platform

CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes

MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy

MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms

FDA rejects Vanda’s jet lag drug in current form

Vanda strongly disputes the FDA’s reasoning

Alembic announces USFDA tentative approval for Bosutinib tablets

EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies

The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue

Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients

Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories

Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection

The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit

NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial

The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases